NOVARTIS’ PAY-OUT APPEAL LESS IN DEMAND, FOR NOW (ADD; 8% UPSIDE)
21/12/20 -"2020 ridiculed various market notions, including the long-held principle of defensive investing in turbulent times. Hence, year-to-date, the Pharma sector lost 0.9% in value, which was not far away ..."
Pages
70
Language
English
Published on
21/12/20
You may also be interested by these reports :
14/07/26
Pharmas’ AI investments pour broadly into two areas: Compute infrastructure, and AI models and platforms. Neither provides a long-term competitive ...
07/07/26
Following the June 2026 phase III R&D setback for an investigational drug, Riliprubart, targeting a rare neurological disease called CIDP (chronic ...
06/07/26
Our target price has been adjusted downward as we have removed the 20% premium associated with peer-based valuation metrics. This adjustment is due ...
30/06/26
The recent US Supreme Court decision in the Roundup litigations, went in favour of Bayer, and brings the firm very close to ending this chapter. Even ...